FibroBiologics, Inc. has announced a significant corporate action involving a one-for-twenty reverse stock split of its common stock, effective March 30, 2026. This decision was formalized through a Certificate of Amendment to the Company's Amended and Restated Certificate of Incorporation, which was filed with the Secretary of State of Delaware on March 25, 2026. The reverse stock split will convert every twenty shares of the Company's common stock into one share, thereby reducing the total number of outstanding shares. The CUSIP number for the common stock will change to 31573L204, while the trading symbol will remain 'FBLG'. This action is expected to enhance the marketability of the stock by potentially increasing its per-share price, which may attract a broader range of investors. The reverse stock split will not affect the overall market capitalization of the Company, as it is a purely mechanical adjustment. However, it is important to note that no fractional shares will be issued; any resulting fractional shares will be rounded up to the nearest whole share. This move is part of the Company's strategy to improve its stock price and maintain compliance with listing requirements on the Nasdaq Stock Market. The Company believes that this action will provide a more favorable investment environment for its shareholders and enhance its ability to raise capital in the future.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.